TNFRSF8 and mycosis fungoides: Brentuximab vedotin, an antibody–drug conjugate made of anti-CD30 and monomethyl auristatin E, is approved to treat transformed CD30+ mycosis fungoides and was shown to eliminate bystander cells which highly express CD30 as well [45,65].